Medicine and Dentistry
Overall Survival
100%
Connective Tissue Cancer
89%
Soft Tissue Sarcoma
89%
Surgery
85%
Malignant Neoplasm
80%
Surgeon
60%
Diseases
53%
Cytoreductive Surgery
52%
Neoplasm
49%
Recurrent Disease
45%
Adenocarcinoma
42%
Medicare
42%
Hyperthermic Intraperitoneal Chemotherapy
41%
Radiation Therapy
37%
Hazard Ratio
37%
Comorbidity
35%
General Surgery
34%
Cancer Surgery
33%
Recurrence Free Survival
32%
Biological Marker
31%
Appendix Tumor
30%
Arm
29%
Preoperative Radiotherapy
29%
Surgical Oncology
27%
Liposarcoma
27%
Bariatric Surgery
27%
Symptomatic Treatment
27%
Gastrointestinal Stromal Tumor
27%
Neurofibromatosis Type I
27%
Well Differentiated Liposarcoma
27%
Dedifferentiated Liposarcoma
25%
Cancer
23%
Quality Improvement
22%
Health Care Cost
22%
Wound Complication
19%
Retroperitoneal Lymph Node Dissection
18%
Colectomy
18%
Metastatic Carcinoma
18%
Malignant Peripheral Nerve Sheath Tumor
17%
Tumor Progression
17%
Perioperative Period
16%
Bevacizumab
16%
COVID-19
16%
Patient-Reported Outcome
16%
Immunity
15%
Leiomyosarcoma
15%
External Beam Radiotherapy
15%
Musculoskeletal Tumor
15%
Disease Free Survival
15%
Percutaneous Coronary Intervention
15%
Keyphrases
Soft Tissue Sarcoma
62%
Appendiceal Adenocarcinoma
54%
Overall Survival
44%
Resection
43%
Dedifferentiated Liposarcoma (DDLPS)
36%
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
36%
Confidence Interval
34%
Surgeons
32%
Cytoreductive Surgery
31%
Accreditation Council for Graduate Medical Education (ACGME)
30%
Surgical Outcomes
28%
Duty Hour Regulation
27%
In Cancer
27%
Surgical Patients
27%
Recurrence-free Survival
27%
Palliative Care
24%
Hazard Ratio
24%
Retrospective Review
20%
Odds Ratio
20%
Local Control
19%
Re-excision
19%
Chemotherapy
18%
Single Institution Study
17%
Malignant Peripheral Nerve Sheath Tumor (MPNST)
17%
Undifferentiated Pleomorphic Sarcoma
16%
Surgical Oncology
16%
Patients with Advanced Cancer
16%
Excision
16%
Surveillance Strategy
16%
Unplanned Excision
16%
Bevacizumab
15%
Patient-reported Outcomes
15%
Duty Hours
15%
Treatment Strategy
15%
Sarcoma
15%
Peritoneal Cancer Index
15%
Readmission
15%
Patient Selection
14%
Systemic Chemotherapy
14%
Tumor
14%
Non-teaching Hospital
13%
Biomarker Analysis
13%
Secondary Cytoreductive Surgery
13%
Entrustment
13%
Sentinel Lymph Node Biopsy
13%
Lung Metastasis
13%
Neoadjuvant
13%
Palliative Care Consultation
13%
Monotherapy
13%
Relative Risk
13%